REDWOOD CITY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from eight studies of the company's Oncotype DX(R) breast cancer test are scheduled to be presented at the 30th Annual San Antonio Breast Cancer Symposium, taking place December 13-16, 2007. Oncotype DX is a multi-gene expression test that physicians use to predict the likelihood of recurrence and the likelihood of chemotherapy benefit for a large portion of early-stage breast cancer patients.
Following are details for each embargoed session (all times are Central
Thursday, Dec. 13, 2007, 9:15 to 9:30 a.m.
Late-Breaking oral presentation: "Prognostic and predictive value of the
21-gene Recurrence Score assay in postmenopausal, node-positive, ER
positive breast cancer.
"Presenter: Kathy S. Albain, M.D.
Thursday, Dec. 13, 2007, 5 to 7 p.m.
Poster presentation: Recurrence Score by Oncotype DX evaluated on the
primary breast tumor predicts the 2-year survival after first relapse.
Presenter: Giampaolo Bianchini, M.D.
Poster presentation: "Prospective multi-center study of the impact of the
21-gene Recurrence Score assay on patient satisfaction, anxiety and
decisional conflict for adjuvant breast cancer treatment
"Presenter: Patricia B. Mumby, Ph.D.
Friday, Dec. 14, 7 to 9 a.m.
Poster presentation: "A retrospective analysis of the impact of Oncotype
DX low Recurrence Score results on treatment decisions in a single
academic breast cancer center.
"Presenter: Hongmei Liang, M.D., Ph.D.
Friday, Dec. 14, 5 to 7 p.m.
Poster presentation: "Gene expression by standardized quantitative RT-PCR
in the special histologic subtypes of estrogen receptor positive invasive
"Presenter: Frederick L. Baehner, M.D.
Poster presentation: "Evaluation of practice patterns in the treatment of
node-negative, hormone-receptor positive breast cancer patients with the
use of the Oncotype DX assay at the University of Pennsylvania.
"Presenter: Christopher Erb, M.D., Ph.D.
Saturday, Dec. 15, 4 to 4:15 p.m.
Oral presentation: "Prognostic utility of the 21-gene assay
compared with Adjuvant! in hormone receptor (HR) positive operable breast
cancer with 0-3 positive axillary nodes treated with adjuvant
chemohormonal therapy (CHT): an analysis of intergroup trial
"Presenter: Lori J. Goldstein, M.D.
Saturday, Dec. 15, 5 to 7 p.m.
Poster presentation: "Estrogen receptor and breast cancer survival in a
Kaiser Permanente population-based study: comparison of quantitative
reverse transcriptase polymerase chain reaction and
"Presenter: Laurel A. Habel, M.D.
About Oncotype DX(R)
Oncotype DX is the first diagnostic multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of breast cancer survival and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 3,300 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, nearly 7,000 physicians have ordered more than 40,000 tests, and health plans covering over 50 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. The American Society of Clinical Oncologists (ASCO) recommends the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.
About Genomic Health
Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.
NOTE: Genomic Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
|SOURCE Genomic Health, Inc.|
Copyright©2007 PR Newswire.
All rights reserved